| Ytd | 73.77% | |
| 1y | -77.08% |
| Open | 6.06 | Prev Close | 5.96 | Low | 5.34 | High | 6.79 | Mkt Cap | 3.48M |
| Vol | 586.57K | Avg Vol | 38.93K | EPS | -101.07 | P/E | N/A | Forward P/E | -1.10 |
| Beta | 1.35 | Short Ratio | 1.65 | Inst. Own | 0.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 8.34 | 200-d Avg | 30.08 | 1yr Est | 5.00 |
ARTL News
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a significant decline in short interes
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Beg
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stag
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“A
The Patent Claims are for the Intended Commercial Formulation of ART27.13Expected to Extend Patent P
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 per
SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Ar
Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinica
The peer-reviewed evaluation analyzed the efficacy, pharmacokinetics, and safety data obtained from
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stag
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Manag
Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market sess
Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, reg
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those exper
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those exper
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stag
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity a
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulati
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.1
The presentations include results from the Phase 1 clinical study of ART26.12 as well as new biomark
First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Eng
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage
Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicin
U.S. stocks traded mixed, Nasdaq down 0.3%. Dow up 0.59%, S&P 500 down 0.09%. Consumer discretio
US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, en
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares ro
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD
Liveramp Holdings Inc (NYSE: RAMP) rose in pre-market trading after being acquired by Publicis for $
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(4.00) per share which missed the ana
SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Art
https://www.sec.gov/Archives/edgar/data/1621221/000164033426000820/artl_s3.htm
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulatin
SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a
Artelo Biosciences, Inc. (NASDAQ:ARTL) shares jumped on Monday after the company announced the publi
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Mu
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multip
SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a
A look at the most-searched tickers on Benzinga Pro for the month of March shows several newcomers a
Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its s
SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) tod